Prevalence of Undiagnosed Monkeypox Virus Infections during Global Mpox Outbreak, United States, June–September 2022
Faisal S. Minhaj, Vijay Singh, Stephanie E. Cohen, Michael B. Townsend, Hyman Scott, John D. Szumowski, C. Bradley Hare, Pallavi Upadhyay, Jairus Reddy, Barbara D. Alexander, Nicolle Baird, Terese Navarra, Lalita Priyamvada, Nhien T. Wynn, William Carson, Solomon Odafe, Sarah Anne J. Guagliardo, Emily Sims, Agam K. Rao, Panayampalli S. Satheshkumar, Paul J. Weidle, Christina L. Hutson
Abstract
Since May 2022, mpox has been identified in 108 countries without endemic disease; most cases have been in gay, bisexual, or other men who have sex with men. To determine number of missed cases, we conducted 2 studies during June-September 2022: a prospective serologic survey detecting orthopoxvirus antibodies among men who have sex with men in San Francisco, California, and a retrospective monkeypox virus PCR testing of swab specimens submitted for other infectious disease testing among all patients across the United States. The serosurvey of 225 participants (median age 34 years) detected 18 (8.0%) who were orthopoxvirus IgG positive and 3 (1.3%) who were also orthopoxvirus IgM positive. The retrospective PCR study of 1,196 patients (median age 30 years; 54.8% male) detected 67 (5.6%) specimens positive for monkeypox virus. There are likely few undiagnosed cases of mpox in regions where sexual healthcare is accessible and patient and clinician awareness about mpox is increased.